Bio-thera Solutions

This early-phase study tested a new drug called BAT4706 in 28 adults with advanced solid tumors (including melanoma) who had no other standard treatment options. The main goal was to check the drug's safety and find the highest dose that people can tolerate. This is a first step …

This study looked at how well and how safely a biosimilar drug called QLETLI (adalimumab) works for children and teenagers aged 4 to 17 with severe plaque psoriasis. 80 participants were treated and monitored for 24 weeks. The main goal was to see if the drug could significantly …

This study tested a new medicine called BAT5906 against a standard treatment (Lucentis) for wet age-related macular degeneration, a leading cause of vision loss in older adults. About 488 people aged 50-85 with active disease took part. The goal was to see if BAT5906 works as wel…

This early-stage study tested a new drug called BAT8006 in 216 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find the highest safe dose, and see how the drug moves through the body. This is not a cure bu…

This early-stage study tested a new drug called BAT1308 in 59 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to find the highest safe dose and check for side effects. Researchers also looked at how the drug moves through th…

This early-phase study tested a new drug called BAT8010 in 23 people with advanced or spreading solid tumors who had no other standard treatment options. The main goals were to check the drug's safety, find the highest safe dose, and see if it could shrink tumors. Participants re…